http://www.zibb.com/all/theme/cq/Alkermes+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 16 Nov 2009 10:30:20 GMTMon, 16 Nov 2009 10:30:20 GMT608831http://www.zibb.com/all/theme/cq/Alkermes+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/5671569/ALKS+Positive+Phase+Results+for+Naltrexone+ER+InjectableBy Fain Hughes, fhughes@knobias.com Alkermes, Inc. (ALKS) announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint andhttp://www.zibb.com/article/5671569/ALKS+Positive+Phase+Results+for+Naltrexone+ER+InjectableAlkermes IncorporatedMon, 16 Nov 2009 10:30:20 GMThttp://www.alkermes.com/At Alkermes, we develop innovative medicines with the potential to change peoples lives for the better. We start by looking at the everyday needs and challenges of patients living with disease.http://www.alkermes.com/Alkermes Incorporatedhttp://www.bmocm.com/research/equities/us/researchnews/default.aspx?id=1022But with a four-week Consta version underway, and a wealth of experience with the product, we believe this franchise can still post modest growth. Exenatide LAR. Lilly/Amylin are to file once-weekly Byetta by mid-year 2009.http://www.bmocm.com/research/equities/us/researchnews/default.aspx?id=1022Alkermes IncorporatedMon, 13 Apr 2009 00:00:00 GMThttp://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=Alkermes+Inc+&Image=&symb=ALKSCopyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=Alkermes+Inc+&Image=&symb=ALKSAlkermes Incorporatedhttp://www.icongrouponline.com/pr/Alkermes_Inc_US/PR.htmlSAN DIEGO, CA -- – ICON Group International Ltd. today released two of the most comprehensive studies to date on vertical gap analysis and labor productivity benchmarks for Alkermes Inc. (NAS: ALKS).http://www.icongrouponline.com/pr/Alkermes_Inc_US/PR.htmlAlkermes Incorporatedhttp://www.in-pharmatechnologist.com/news/ng.asp?n=57919-alkermes-to-fileAlkermes to file first 'homegrown' product US drug delivery company Alkermes has entered a new stage in its development as it gears up to filehttp://www.in-pharmatechnologist.com/news/ng.asp?n=57919-alkermes-to-fileAlkermes Incorporatedhttp://www.biz-lib.com/ZEB67427.htmlAlkermes Inc is building a pharmaceutical company using drug delivery as a springboard. The company is taking progressive steps, building its drug-delivery capabilities and technologies, then leveraging them to develop its first commercial products.http://www.biz-lib.com/ZEB67427.htmlAlkermes Incorporatedhttp://uk.finance.yahoo.com/q?s=ALKSCopyright 2007 (c) Yahoo! UK Ltd. All rights reserved. Questions | Disclaimer | Quotes Information Quotes delayed except where indicated otherwise. Delay time is 20 mins for London stock exchange. See also delay times for other exchanges.http://uk.finance.yahoo.com/q?s=ALKSAlkermes Incorporatedhttp://www.drugs.com/nda/vivitrol_060217.htmlDrugs.com - prescription drug and over the counter medicine information available on over 24,000 approved medications and pharmaceuticals, including side effects and drug interactions.http://www.drugs.com/nda/vivitrol_060217.htmlAlkermes Incorporatedhttp://www.evaluatepharma.com/CoInfo/CoInfo-ALKS.htmEvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.http://www.evaluatepharma.com/CoInfo/CoInfo-ALKS.htmAlkermes Incorporatedhttp://www.rtmagazine.com/prnews.php?p=215. VIVITROL is indicated for patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment.http://www.rtmagazine.com/prnews.php?p=215Alkermes Incorporatedhttp://www.eyeforpharma.com/search.asp?news=32326CAMBRIDGE, Mass. --Sept. 30, 2002--Alkermes, Inc., today announced the appointment of Joseph Anisko, Ph.D., to the new position of Vice President of Quality. In his new role at Alkermes, Dr. Anisko will be responsible for all aspects of quality operations and compliance activities. Dr.http://www.eyeforpharma.com/search.asp?news=32326Alkermes Incorporatedhttp://www.quotelinks.com/companies/alks.htmlStock quotes, news and charts for Alkermes, Inc. Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/alks.htmlAlkermes Incorporatedhttp://www.apria.com/resources/1,2725,494-858795,00.htmlNEW YORK, Dec 11 (Reuters) - Amylin Pharmaceuticals shares jumped more than 30 percent on Thursday after the company and its partners said they would seek approval for their closely watched long-acting version of the diabetes treatment Byetta by the middle of next year.http://www.apria.com/resources/1,2725,494-858795,00.htmlAlkermes Incorporatedhttp://www.forestcity.net/projects_printable.asp?key={218F1DEB-0505-4FE3-97D4-CB47209F012B}University Park is an award-winning campus environment of 2.3 million square feet, just steps from the Massachusetts Institute of Technology and minutes from the renowned research and academic institutions of Boston Date opened/acquired 2002 Square footage 145,275http://www.forestcity.net/projects_printable.asp?key={218F1DEB-0505-4FE3-97D4-CB47209F012B}Alkermes Incorporatedhttp://www.newratings.com/headlines/Alkermes_US01642T1088.htmlCopyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.http://www.newratings.com/headlines/Alkermes_US01642T1088.htmlAlkermes Incorporatedhttp://www.investorguide.com/stock-news.cgi?ticker=ALKSTrack Any Stock Instantly Just enter up to ten of your stocks in the Stock Tracker box, click the ADD button beside any of Today's Hot Stocks, or click ADD beside any of the stocks you've Recently Viewed.http://www.investorguide.com/stock-news.cgi?ticker=ALKSAlkermes Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=279592006 MAY 17 - (NewsRx.com) -- Alkermes, Inc., (ALKS) and Cephalon, Inc., (CEPH) announced that the U.S. Food and Drug Administration (FDA) has approved Vivitrol (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence.http://www.pharmacychoice.com/News/article.cfm?Article_ID=27959Alkermes Incorporatedhttp://www.fiercebiotech.com/story/alkermes-inks-rich-collaboration-deal-for-vivitrex/2005-06-24FierceBiotech is the biotech industry daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and fda approval news.http://www.fiercebiotech.com/story/alkermes-inks-rich-collaboration-deal-for-vivitrex/2005-06-24Alkermes Incorporatedhttp://www.cephalon.com/newsroom/news_reader.aspx?ID=799265The New Drug Application (NDA) for VIVITROL, formerly known as VIVITREX®, was submitted on March 31, 2005. Alkermes and Cephalon continue to prepare for the launch of VIVITROL during the second quarter of 2006.http://www.cephalon.com/newsroom/news_reader.aspx?ID=799265Alkermes Incorporatedhttp://www.pcquote.com/stocks/index.php?symbols=ALKSPowered by Money.net Business Solutions, the leading provider of professional-quality, customized market data and enterprise content solutions for investors, media companies, and financial institutions. For Sales Information Contact: (212) 334-2000.http://www.pcquote.com/stocks/index.php?symbols=ALKSAlkermes Incorporatedhttp://www.goodwinprocter.com/News_Events/News/Alkermes_Inc__Announces_Signif.aspxJan. 4, 2006 — The federal district court in Boston recently dismissed — with prejudice and in its entirety — securities class action litigation that had been filed against our client Alkermes Inc.http://www.goodwinprocter.com/News_Events/News/Alkermes_Inc__Announces_Signif.aspxAlkermes Incorporatedhttp://www.thelabrat.com/jobs/companies/Alkermes.shtmlAlkermes is focused on drug delivery. There are several partnered programs as well as in-house development activites.http://www.thelabrat.com/jobs/companies/Alkermes.shtmlAlkermes Incorporatedhttp://www.thestreet.com/print/story/10434226.htmlEach business day, TheStreet.com Ratings updates its ratings on the stocks it covers. The proprietary ratings model projects a stock's total return potential over a 12-month period, including both price appreciation and dividends.http://www.thestreet.com/print/story/10434226.htmlAlkermes Incorporatedhttp://www.researchandmarkets.com/reports/354643/impact_of_inhaled_insulin_on_the_insulin.pdfDescription: The first inhaled formulation of rapid-acting insulin, Pfizer’s Exubera, has just reached the market. Several other inhaled insulins are now in late-stage development.http://www.researchandmarkets.com/reports/354643/impact_of_inhaled_insulin_on_the_insulin.pdfAlkermes Incorporated